Literature DB >> 27894849

A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity.

Jiapei Lu1, William Wang1, Menglin Xu1, Yuping Li1, Chengshui Chen1, Xiangdong Wang2.   

Abstract

A number of new biotechnologies are used to identify potential biomarkers for the early detection of lung cancer, enabling a personalized therapy to be developed in response. The combinatorial cross-regulation of hundreds of biological function-specific transcription factors (TFs) is defined as the understanding of regulatory networks of molecules within the cell. Here we integrated global databases with 537 patients with lung adenocarcinoma (ADC), 140 with lung squamous carcinoma (SCC), 9 with lung large-cell carcinoma (LCC), 56 with small-cell lung cancer (SCLC), and 590 without cancer with the understanding of TF functions. The present review aims at the homogeneity or heterogeneity of gene expression profiles among subtypes of lung cancer. About 5, 136, 52, or 16 up-regulated or 19, 24, 122, or 97down-regulated type-special TF genes were identified in ADC, SCC, LCC or SCLC, respectively. DNA-binding and transcription regulator activity associated genes play a dominant role in the differentiation of subtypes in lung cancer. Subtype-specific TF gene regulatory networks with elements should be an alternative for diagnostic and therapeutic targets for early identification of lung cancer and can provide insightful clues to etiology and pathogenesis. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bioinformatics; Lung cancer; Regulatory network; Subtype; Transcriptional factor

Mesh:

Substances:

Year:  2016        PMID: 27894849     DOI: 10.1016/j.semcancer.2016.11.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  6 in total

1.  Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.

Authors:  Lin Wang; Chuanhao Tang; Bin Xu; Lin Yang; Lili Qu; Liangliang Li; Xiaoyan Li; Weixia Wang; Haifeng Qin; Hongjun Gao; Kun He; Xiaoqing Liu
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

2.  EGFR mutations subset in Chinese lung squamous cell carcinoma patients.

Authors:  Ying Sun; Xin Yin; Miao-Miao Wen; Jiao Zhang; Xue-Jiao Wang; Jing-Hua Xia; Yan-Ning Zhang; Zhi-Pei Zhang; Xiao-Fei Li
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

3.  Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis.

Authors:  Jin-Wu Hu; Guang-Yu Ding; Pei-Yao Fu; Wei-Guo Tang; Qi-Man Sun; Xiao-Dong Zhu; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun; Cheng Huang
Journal:  Biomed Res Int       Date:  2020-03-22       Impact factor: 3.411

4.  Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.

Authors:  Shaocong Wu; Min Luo; Kenneth K W To; Jianye Zhang; Chaoyue Su; Hong Zhang; Sainan An; Fang Wang; Da Chen; Liwu Fu
Journal:  Mol Cancer       Date:  2021-01-18       Impact factor: 27.401

5.  Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion.

Authors:  Yanzhuo Luo; Bingjin Li; Guangxin Zhang; Yuxiao He; Jeeyoo Hope Bae; Fengping Hu; Ranji Cui; Runhua Liu; Zhou Wang; Lizhong Wang
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

6.  Heterogeneity of lipidomic profiles among lung cancer subtypes of patients.

Authors:  Jiapei Lv; Danyan Gao; Yong Zhang; Duojiao Wu; Lihua Shen; Xiangdong Wang
Journal:  J Cell Mol Med       Date:  2018-07-12       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.